NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN OR SUCH
OTHER JURISDICTIONS WHERE THE OFFERING AND SALE OF THE NEW SHARES AND
THE SUBSCRIPTION RIGHTS IS RESTRICTED BY LAW.
DiaGenic ASA
Reference is made to the stock exchange announcements made by DiaGenic
ASA ("DiaGenic" or the "Company") on 14 March 2014 regarding the
approved prospectus for the rights offering (the "Rights Offering") and
subsequent listing of 100,000,000 new shares (the "New Shares") each
with a par value of NOK 0.20 at a subscription price of NOK 0.50 per New
Share (the "Prospectus")
Subscription Period for the Rights Offering:
The subscription period for the Rights Issue commences today, 17 March
2014 and expires at 17:30 hours, Central European Time ("CET"), on 31
March 2014 (the "Subscription Period"). The Subscription Rights will be
tradable on Oslo Børs during the Subscription Period under the ticker
symbol "DIAG S". Last day of trading in the subscription rights is 31
March 2014. The subscription rights must be used before expiry of the
subscription period, or sold at the latest 31 March 2014.
Subscription rights (the "Subscription Rights") will be granted to
existing shareholders (the "Existing Shareholders") of DiaGenic as of
the end of 25 February 2014 as appearing in the Norwegian Central
Securities Depository ("VPS") on 28 February 2014 (the "Record Date").
The Rights Offering is fully underwritten by an underwriting syndicate.
Each Eligible Shareholder will be granted 12.25509 Subscription Rights
for each Share registered as held by such Eligible Shareholder as of the
Record Date rounded down to the nearest whole Subscription Right. Each
Subscription Right will, subject to applicable securities laws, give the
right to subscribe for and be allocated one New Share. Oversubscription
and subscription without Subscription Rights is permitted.
Important notice: Subscription Rights that are not used to subscribe for
New Shares before the end of the Subscription Period will have no value
and will lapse without compensation to the holder. Shareholders not
using their subscription rights will have their shareholding
significantly diluted.
The Subscription rights are tradable and are, based on recent trading,
expected to have a financial value as DiaGenic's shares are currently
traded at a higher price than the subscription price.
Manager for the Rights Issue is Arctic Securities ASA
The information in this notice is not complete. For further information
see Prospectus dated 14 March 2014 which is available online at
www.diagenic.com and www.arcticsec.no. The Prospectus can also be
obtained physically from the Manager and will be available to the public
from 17 March 2014:
The Manager:
Arctic Securities ASA
P.O. Box 1833 Vika
Haakon VII's gt. 5
0123 Oslo
Norway
www.arcticsec.no